AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
91_CD
17_CD
Loans_NN
Repayment_NOMZ
2004_CD
2003_CD
dates_NN
$_$
m_CD
$_$
m_CD [BEMA]
Unsecured_JJ
loans_NN
US_FPP1
dollars_NN
7_CD
%_NN
Guaranteed_VBN [PUBV]
debentures_NN
2023 283 295_CD
5.4_CD
%_NN
Callable_JJ
bond_NN
2014_CD
747_CD
Others_NN
2013_CD
8_CD
Total_JJ
unsecured_JJ
1,030_CD
303_CD
Less_RB
:_:
current_JJ
instalments_NOMZ
of_PIN
loans_NN
Loans_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
1,030_CD
303_CD
In_PIN
the_DT
above_PLACE
table_NN
,_,
loans_NN
are_VPRT [PASS]
shown_VBN [PRIV]
after_IN
taking_VBG
account_NN
of_PIN
associated_VBN
cross-currency_NN
swaps_NN
see_VPRT [PRIV]
Note_NN
18_CD
._.
During_PIN
the_DT
year_NN
,_,
a_DT
5.4_CD
%_NN
callable_JJ
bond_NN
was_VBD [PASS]
issued_VBN
for_PIN
proceeds_NN
,_,
net_NN
of_PIN
expense_NN
,_,
of_PIN
$_$
747m_CD
._.
There_EX
are_VPRT
no_SYNE
loans_NN
from_PIN
banks_NN
included_VBD
in_PIN
the_DT
table_NN
above_PLACE
2003_CD
$_$
nil_JJ
._.
18_CD
Financial_NN
instruments_NOMZ
The_DT
Groups_NN
objectives_NN
,_,
policies_NN
and_PHC
strategy_NN
in_PIN
respect_NN
of_PIN
risk_NN
management_NOMZ
and_CC
the_DT
use_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
described_VBN
in_PIN
the_DT
Financial_NN
Review_NN
._.
The_DT
following_JJ
disclosures_NN
exclude_VPRT
all_QUAN
short_JJ
term_NN
,_,
trade_NN
related_VBN
debtors_NN
and_PHC
creditors_NN
._.
Interest_NN
rate_NN
risks_NN
of_PIN
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
The_DT
interest_NN
rate_NN
profile_NN
,_,
after_IN
taking_VBG
into_PIN
account_NN
interest_NN
and_PHC
cross-currency_NN
swaps_NN
,_,
of_PIN
the_DT
financial_JJ
assets_NN
and_PHC
liabilities_NOMZ
of_PIN
the_DT
Group_NN
as_IN
at_PIN
31_CD
December_NN
2004_CD
was_VBD
:_:
Financial_NN
Weighted_NN
Weighted_NN
assets_NN
liabilities_NOMZ
average_JJ
average_NN
on_PIN
which_WDT [PIRE]
fixed_JJ
period_NN
for_PIN
Floating_VBG
Fixed_VBN
no_SYNE
interest_NN
is_VPRT
interest_NN
which_WDT [WHOBJ]
rate_NN
rate_NN
rate_NN
paid_VBD
received_VBN
Total_JJ
rate_NN
is_VPRT [PASS]
fixed_VBN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
%_NN
Years_NN
Financial_NN
liabilities_NOMZ
US_FPP1
dollar_NN
1,159_CD
1,159_CD
Other_JJ
13_CD
13_CD
1,172_CD
1,172_CD
Financial_NN
assets_NN
US_FPP1
dollar_NN
4,772_CD
10_CD
4,782_CD
Euro_NN
4_CD
4_CD
Sterling_GER
127 252 379_CD
SEK_NN
2_CD
18_CD
20_CD
Other_JJ
228_CD
228_CD
5,133_CD
280_CD
5,413_CD
The_DT
floating_VBG
rate_NN
financial_JJ
liabilities_NOMZ
comprise_VPRT
largely_RB
of_PIN
fixed_JJ
rate_NN
debt_NN
that_TSUB
has_VPRT [PEAS]
been_VBN [PASS]
swapped_VBN
into_PIN
floating_VBG
rate_NN
debt_NN
._.
During_PIN
the_DT
year_NN
,_,
the_DT
Group_NN
restructured_VBD
its_PIT
external_JJ
debt_NN
._.
A_DT
$_$
300m_CD
US_FPP1
dollar_NN
bond_NN
was_VBD [BEMA]
partially_DWNT
re-purchased_PRED
and_CC
canceled_VBN
,_,
with_PIN
the_DT
remaining_VBG
balance_NN
swapped_VBD
into_PIN
floating_VBG
rate_NN
until_IN
maturity_NOMZ
._.
In_CONJ
addition_NULL
,_,
the_DT
Group_NN
issued_VBD
a_DT
$_$
750m_CD
US_FPP1
dollar_NN
fixed_VBN
rate_NN
bond_NN
under_IN
a_DT
$_$
4bn_CD
SEC_NN
registered_VBD
shelf_NN
program_NN
._.
The_DT
bond_NN
matures_VPRT
in_PIN
2014_CD
and_CC
has_VPRT [PEAS]
been_VBN [PASS]
swapped_VBN
to_TO
floating_VBG
rate_NN
until_IN
maturity_NOMZ
._.
The_DT
financial_JJ
liabilities_NOMZ
also_RB
include_VPRT
$_$
142m_CD
of_PIN
short_JJ
term_NN
bank_NN
borrowings_GER
and_PHC
overdrafts_NN
,_,
bearing_VBG
interest_NN
at_PIN
rates_NN
fixed_VBN [WZPAST]
by_PIN
reference_NN
to_PIN
local_JJ
interbank_NN
rates_NN
._.
The_DT
financial_JJ
assets_NN
principally_RB
comprise_VPRT
cash_NN
on_PIN
overnight_JJ
deposit_NN
or_CC
held_VBN [PRIV]
directly_RB
with_PIN
third_JJ
party_NN
fund_NN
managers_NN
and_CC
short_JJ
term_NN
investments_NOMZ
with_PIN
an_DT
average_JJ
maturity_NOMZ
of_PIN
27_CD
days_NN
._.
These_DEMP
include_VPRT
deposits_NN
where_RB
the_DT
interest_NN
rate_NN
is_VPRT [PASS]
fixed_VBN
until_IN
maturity_NOMZ
but_CC
,_,
as_IN
the_DT
original_JJ
maturity_NOMZ
is_VPRT [BEMA]
less_PRED
than_PIN
one_CD
year_NN
,_,
they_TPP3
are_VPRT [PASS]
classified_VBN
as_IN
floating_VBG
rate_NN
financial_JJ
instruments_NOMZ
._.
The_DT
main_JJ
benchmark_NN
rates_NN
for_PIN
euro_NN
and_PHC
US_FPP1
dollar_NN
financial_JJ
assets_NN
are_VPRT [BEMA]
the_DT
relevant_JJ
LIBID_NN
rates_NN
._.
Financial_JJ
assets_NN
include_VPRT
$_$
267m_CD
of_PIN
other_JJ
fixed_JJ
asset_NN
investments_NOMZ
on_PIN
which_WDT [PIRE]
no_SYNE
interest_NN
is_VPRT [PASS]
received_VBN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
92_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
18_CD
Financial_NN
instruments_NOMZ
continued_VBD
Currency_NN
exposures_NN
100_CD
%_NN
of_PIN
the_DT
Groups_NN
major_JJ
transactional_JJ
currency_NN
exposures_NN
on_PIN
working_VBG
capital_NN
balances_NN
,_,
which_WDT [SERE]
typically_RB
extend_VPRT
for_PIN
up_RB
to_PIN
three_CD
months_NN
,_,
are_VPRT [PASS]
hedged_VBN
using_VBG
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
as_RB
at_PIN
31_CD
December_NN
2004_CD
and_CC
31_CD
December_NN
2003_CD
,_,
there_EX
were_VBD
no_SYNE
material_NN
monetary_JJ
assets_NN
or_CC
liabilities_NOMZ
in_PIN
currencies_NN
other_JJ
than_PIN
the_DT
functional_JJ
currencies_NN
of_PIN
the_DT
Group_NN
companies_NN
concerned_VBN
,_,
having_VBG [PEAS]
taken_VBN
into_PIN
account_NN
the_DT
effect_NN
of_PIN
forward_RB
exchange_NN
currency_NN
contracts_NN
that_TSUB
have_VPRT [PEAS]
been_VBN [PASS]
used_VBN
to_TO
match_VB
foreign_JJ
currency_NN
exposures_NN
._.
Additionally_RB
,_,
approximately_RB
95_CD
%_NN
of_PIN
forecast_NN
future_JJ
foreign_JJ
currency_NN
transaction_NOMZ
exposures_NN
on_PIN
major_JJ
currencies_NN
extending_VBG [WZPRES]
for_PIN
12_CD
months_NN
were_VBD [PASS]
hedged_VBN
to_TO
cover_VB
movements_NOMZ
outside_PLACE
specified_VBN
limits_NN
._.
The_DT
principal_JJ
currency_NN
exposures_NN
sterling_GER
,_,
Swedish_JJ
kronor_NN
SEK_NN
and_PHC
euros_NN
were_VBD [PASS]
hedged_VBN
using_VBG
a_DT
mixture_NN
of_PIN
purchased_JJ
currency_NN
options_NOMZ
and_CC
forward_RB
foreign_JJ
exchange_NN
contracts_NN
._.
As_IN
at_PIN
31_CD
December_NN
2004_CD
,_,
the_DT
forecast_NN
future_JJ
foreign_JJ
currency_NN
transaction_NOMZ
exposures_NN
were_VBD
:_:
2004_CD
2003_CD
Forecast_NN
Forecast_NN
exposures_NN
exposures_NN
$_$
m_CD
$_$
m_CD
Sterling_GER
payables_NN
2,553_CD
2,517_CD
SEK_NN
payables_NN
1,551_CD
1,442_CD
Euro_NN
receivables_NN
1,926_CD
2,194_CD
Maturity_NOMZ
of_PIN
financial_JJ
liabilities_NOMZ
The_DT
maturity_NOMZ
profile_NN
of_PIN
the_DT
Groups_NN
financial_JJ
liabilities_NOMZ
,_,
other_JJ
than_PIN
short_JJ
term_NN
creditors_NN
such_JJ
as_IN
trade_NN
creditors_NN
and_PHC
accruals_NN
,_,
at_PIN
31_CD
December_NN
2004_CD
was_VBD
as_IN
follows_VPRT
:_:
2004_CD
2003_CD
Analysis_NN
by_PIN
year_NN
of_PIN
repayment_NOMZ
Loans_NN
Other_JJ
Total_NN
Loans_NN
Other_JJ
Total_JJ
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
After_IN
five_CD
years_NN
1,030_CD
1,030_CD
303_CD
303_CD
From_PIN
five_CD
to_PIN
four_CD
years_NN
From_PIN
four_CD
to_PIN
three_CD
years_NN
From_PIN
three_CD
to_PIN
two_CD
years_NN
From_PIN
two_CD
to_PIN
one_CD
years_NN
Due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
1,030_CD
1,030_CD
303_CD
303_CD
Due_JJ
within_PIN
one_CD
year_NN
142 142 152 152_CD
1,030_CD
142_CD
1,172_CD
303 152 455_CD
Other_JJ
financial_JJ
liabilities_NOMZ
comprise_VPRT
short_JJ
term_NN
bank_NN
borrowings_GER
and_PHC
overdrafts_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
93_CD
18_CD
Financial_NN
instruments_NOMZ
continued_VBD
Borrowing_GER
facilities_NOMZ
The_DT
Group_NN
currently_RB
relies_VPRT
on_PIN
its_PIT
cash_NN
balances_NN
and_CC
short_JJ
term_NN
investments_NOMZ
excluding_VBG [WZPRES]
investment_NOMZ
securities_NOMZ
of_PIN
$_$
4,990_CD
m_NN
and_CC
long_JJ
term_NN
debt_NN
of_PIN
$_$
1,030_CD
m_NN
to_TO
manage_VB
liquidity_NOMZ
risk_NN
._.
Fair_NN
values_NN
of_PIN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
Set_VPRT
out_PIN
below_PLACE
is_VPRT [BEMA]
a_DT
comparison_NN
by_PIN
category_NN
of_PIN
carrying_VBG
values_NN
and_CC
fair_JJ
values_NN
of_PIN
all_QUAN
the_DT
Groups_NN
financial_JJ
assets_NN
and_CC
financial_JJ
liabilities_NOMZ
as_IN
at_PIN
31_CD
December_NN
2004_CD
and_CC
31_CD
December_NN
2003_CD
._.
2004 2004 2003 2003_CD
Carrying_VBG
Fair_NN
Carrying_VBG [WZPRES]
Fair_NN
value_NN
value_NN
value_NN
value_NN
$_$
m_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Primary_JJ
financial_JJ
instruments_NOMZ
Short_JJ
term_NN
borrowings_GER
and_PHC
overdrafts_NN
142 142 152 152_CD
Loans_NN
1,030_CD
1,126_CD
303_CD
371_CD
Cash_NN
1,055_CD
1,055_CD
733_CD
733_CD
Short_JJ
term_NN
investments_NOMZ
4,091_CD
4,095_CD
3,218_CD
3,306_CD
Fixed_VBN
asset_NN
investments_NOMZ
267 262 220 217_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
to_TO
manage_VB
the_DT
interest_NN
rate_NN
and_PHC
currency_NN
profile_NN
Cross-currency_NN
swaps_NN
and_PHC
interest_NN
rate_NN
swaps_NN
71_CD
56_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
or_CC
issued_VBN
to_TO
hedge_VB
the_DT
currency_NN
exposure_NN
on_PIN
existing_VBG
transactions_NOMZ
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
910_CD
12_CD
12_CD
Derivative_JJ
financial_JJ
instruments_NOMZ
held_VBN [PRIV]
or_CC
issued_VBN
to_TO
hedge_VB
the_DT
currency_NN
exposure_NN
on_PIN
expected_JJ
future_JJ
transactions_NOMZ
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
19_CD
Foreign_JJ
currency_NN
option_NOMZ
contracts_NN
22_CD
32_CD
77_CD
148_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
94_CD
Form_NN
20-F_JJ
Information_NOMZ
2004_CD
Notes_NN
to_PIN
the_DT
Financial_NN
Statements_NOMZ
continued_VBD
18_CD
Financial_NN
instruments_NOMZ
continued_VBD
The_DT
methods_NN
and_PHC
assumptions_NOMZ
used_VBN
to_TO
estimate_VB [PRIV]
the_DT
fair_JJ
values_NN
of_PIN
financial_JJ
instruments_NOMZ
are_VPRT
as_IN
follows_VPRT
:_:
a._VB
Short_JJ
term_NN
investments_NOMZ
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
investments_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
._.
For_PIN
unlisted_JJ
investments_NOMZ
,_,
carrying_VBG
values_NN
approximate_JJ
fair_JJ
value_NN
._.
Fixed_JJ
asset_NN
investments_NOMZ
excluding_VBG [WZPRES]
equity_NOMZ
investments_NOMZ
in_PIN
joint_JJ
ventures_NN
and_PHC
associates_NN
the_DT
fair_JJ
value_NN
of_PIN
listed_VBN
investments_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
._.
c._FW
Loans_NN
the_DT
fair_JJ
value_NN
of_PIN
publicly_RB
traded_VBN
debt_NN
is_VPRT [PASS]
based_VBN
on_PIN
year_NN
end_NN
quoted_VBN
market_NN
prices_NN
:_:
the_DT
fair_JJ
value_NN
of_PIN
floating_VBG
rate_NN
debt_NN
is_VPRT [BEMA]
nominal_JJ
value_NN
,_,
as_IN
mark_NN
to_PIN
market_NN
differences_NN
would_PRMD
be_VB [BEMA]
minimal_PRED
given_VBN
frequency_NN
of_PIN
resets_NN
:_:
the_DT
fair_JJ
value_NN
of_PIN
remaining_VBG
debt_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
appropriate_JJ
zero_CD
coupon_NN
valuation_NOMZ
techniques_NN
based_VBN [WZPAST]
on_PIN
rates_NN
current_JJ
at_PIN
year_NN
end_NN
._.
d._FW
Forward_RB
foreign_JJ
exchange_NN
contracts_NN
the_DT
Group_NN
has_VPRT
forward_RB
foreign_JJ
exchange_NN
contracts_NN
to_TO
sell_VB
currency_NN
for_PIN
the_DT
purpose_NN
of_PIN
hedging_VBG
non-dollar_JJ
commercial_JJ
transaction_NOMZ
exposures_NN
which_WDT [WHSUB]
existed_VBD
at_PIN
the_DT
date_NN
of_PIN
the_DT
balance_NN
sheet_NN
and_CC
to_TO
hedge_VB
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
non-dollar_JJ
commercial_JJ
transactions_NOMZ
for_PIN
2005_CD
._.
The_DT
majority_NOMZ
of_PIN
the_DT
contracts_NN
for_PIN
existing_VBG
transactions_NOMZ
had_VBD
a_DT
maturity_NOMZ
of_PIN
six_CD
months_NN
or_CC
less_JJ
from_PIN
year_NN
end_NN
._.
The_DT
fair_JJ
value_NN
of_PIN
forward_RB
foreign_JJ
exchange_NN
contracts_NN
is_VPRT [PASS]
based_VBN
on_PIN
market_NN
forward_RB
foreign_JJ
exchange_NN
rates_NN
at_PIN
year_NN
end_NN
._.
e._FW
Foreign_JJ
currency_NN
option_NOMZ
contracts_NN
the_DT
Group_NN
has_VPRT
foreign_JJ
currency_NN
option_NOMZ
contracts_NN
to_TO
hedge_VB
anticipated_VBN [PRIV]
,_,
but_CC
not_XX0
firmly_RB
committed_VBN
,_,
non-dollar_JJ
commercial_JJ
transactions_NOMZ
for_PIN
2005_CD
._.
The_DT
fair_JJ
value_NN
of_PIN
option_NOMZ
contracts_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
Black-Scholes_NN
valuation_NOMZ
techniques_NN
._.
f._FW
Interest_NN
rate_NN
and_PHC
cross-currency_NN
swaps_NN
AstraZeneca_NN
uses_VPRT
interest_NN
rate_NN
and_PHC
cross-currency_NN
swaps_NN
to_TO
hedge_VB
the_DT
Groups_NN
exposure_NN
to_PIN
fluctuations_NOMZ
in_PIN
interest_NN
rates_NN
and_CC
foreign_JJ
exchange_NN
movements_NOMZ
on_PIN
borrowings_GER
,_,
in_PIN
accordance_NN
with_PIN
a_DT
formal_JJ
risk_NN
management_NOMZ
strategy_NN
._.
The_DT
fair_JJ
value_NN
is_VPRT [PASS]
estimated_VBN [PRIV]
using_VBG
appropriate_JJ
zero_CD
coupon_NN
valuation_NOMZ
techniques_NN
based_VBN [WZPAST]
on_PIN
rates_NN
current_JJ
at_PIN
year_NN
end_NN
._.
The_DT
above_PLACE
financial_JJ
instruments_NOMZ
are_VPRT [BEMA]
subject_PRED
to_PIN
credit_NN
and_PHC
market_NN
risk_NN
._.
AstraZeneca_NN
contains_VPRT
credit_NN
risk_NN
through_PIN
the_DT
use_NN
of_PIN
counterparty_NN
and_PHC
product_NN
specific_JJ
credit_NN
limits_NN
and_CC
by_PIN
ongoing_JJ
review_NN
procedures_NN
._.
All_QUAN
financial_JJ
instruments_NOMZ
are_VPRT [PASS]
transacted_VBN
with_PIN
commercial_JJ
banks_NN
and_CC
,_,
in_PIN
line_NN
with_PIN
standard_JJ
market_NN
practice_NN
,_,
are_VPRT [PASS]
not_XX0
backed_VBN
with_PIN
cash_NN
collateral_NN
._.
The_DT
notional_JJ
principal_NN
values_NN
of_PIN
off_PIN
balance_NN
sheet_NN
financial_JJ
instruments_NOMZ
do_VPRT
not_XX0
represent_VB
amounts_NN
exchanged_VBN [WZPAST]
by_PIN
the_DT
parties_NN
and_CC
are_VPRT [BEMA]
not_XX0
a_DT
measure_NN
of_PIN
the_DT
credit_NN
risk_NN
to_PIN
the_DT
Group_NN
of_PIN
these_DEMO
instruments_NOMZ
._.
The_DT
credit_NN
risk_NN
of_PIN
these_DEMO
instruments_NOMZ
is_VPRT [PASS]
limited_VBN
to_PIN
the_DT
positive_JJ
fair_JJ
values_NN
of_PIN
such_JJ
contracts_NN
._.
Market_NN
risk_NN
is_VPRT [BEMA]
the_DT
sensitivity_NOMZ
of_PIN
the_DT
value_NN
of_PIN
financial_JJ
instruments_NOMZ
to_PIN
changes_NN
in_PIN
related_JJ
currency_NN
and_PHC
interest_NN
rates_NN
._.
The_DT
Group_NN
is_VPRT [PASS]
not_XX0
exposed_VBN
to_PIN
material_NN
market_NN
risk_NN
because_CAUS
gains_NN
and_PHC
losses_NN
on_PIN
the_DT
derivative_JJ
financial_JJ
instruments_NOMZ
are_VPRT [SPAU] [BYPA]
largely_RB
offset_VBN
by_PIN
gains_NN
and_PHC
losses_NN
on_PIN
the_DT
underlying_VBG
assets_NN
,_,
liabilities_NOMZ
and_PHC
transactions_NOMZ
subject_JJ
to_TO
hedge_VB
._.
Hedges_NN
As_IN
noted_VBN [PRIV]
on_PIN
page_NN
92_CD
,_,
the_DT
Groups_NN
policy_NN
is_VPRT
to_TO
hedge_VB
100_CD
%_NN
of_PIN
transactional_JJ
currency_NN
exposures_NN
and_CC
approximately_RB
95_CD
%_NN
of_PIN
forecast_NN
future_JJ
transaction_NOMZ
exposures_NN
using_VBG [WZPRES]
forward_RB
foreign_JJ
exchange_NN
contracts_NN
and_CC
foreign_JJ
currency_NN
option_NOMZ
contracts_NN
._.
It_PIT
also_RB
uses_VPRT
cross-currency_NN
and_PHC
interest_NN
rate_NN
swaps_NN
to_TO
manage_VB
the_DT
profile_NN
of_PIN
its_PIT
borrowings_GER
._.
Gains_NN
and_PHC
losses_NN
on_PIN
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
exposure_NN
that_DEMP
is_VPRT
being_VBG [PASS]
hedged_VBN
is_VPRT [BEMA] [PASS]
itself_PIT
recognized_VBN [PRIV]
._.
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
instruments_NOMZ
used_VBN [WZPAST]
for_PIN
hedging_VBG
are_VPRT
as_IN
follows_VPRT
:_:
Total_JJ
net_JJ
Gains_NN
Losses_NN
gains_VPRT
$_$
m_CD
$_$
m_CD
$_$
m_CD [BEMA]
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
at_PIN
1_CD
January_NN
2004_CD
129_CD
21_CD
108_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
that_TSUB
were_VBD [PASS]
recognized_VBN [PRIV]
in_PIN
2004_CD
105_CD
21_CD
84_CD
Gains_NN
and_PHC
losses_NN
arising_VBG [WZPRES]
in_PIN
previous_JJ
years_NN
that_TSUB
were_VBD [PASS]
not_XX0
recognized_VBN [PRIV]
in_PIN
2004_CD
24_CD
24_CD
Unrecognised_JJ
gains_NN
and_PHC
losses_NN
on_PIN
hedges_NN
at_PIN
31_CD
December_NN
2004_CD
83_CD
1_CD
82_CD
Gains_NN
and_PHC
losses_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
2005_CD
33_CD
1_CD
32_CD
Gains_NN
and_PHC
losses_NN
expected_VBN [PRIV]
to_TO
be_VB [PASS]
recognized_VBN [PRIV]
in_PIN
2006_CD
or_CC
later_TIME
50_CD
50_CD
